[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Kalvista Pharmaceuticals Inc 200 CROSSING BOULEVARD FRAMINGHAM MA 01702 USA

www.kalvista.com Employees: 270 P: 857-999-0075 F: 866-553-3269

Sector:

Medical

Description:

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 1,369,164
Enterprise Value, $K 1,237,544
Shares Outstanding, K 51,222
Float, K 49,019
% Float 95.70%
Short Interest, K 19,645
Short Float 38.35%
Days to Cover 20.74
Short Volume Ratio 0.21
% of Insider Shareholders 4.30%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 49,080 K
Annual Net Income, $ -109,520 K
Last Quarter Sales, $ 13,690 K
Last Quarter Net Income, $ -49,480 K
EBIT, $ -190,940 K
EBITDA, $ -189,980 K

Growth:

1-Year Return 129.25%
3-Year Return 153.85%
5-Year Return 2.53%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 16.12%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.92 on 11/10/25
Next Earnings Date 03/24/26
Earnings Per Share ttm -3.95
EPS Growth vs. Prev Year 56.57%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-14 on 11/22/16

KALV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -223.15%
Debt/Equity 0.00
Price/Sales 27.93
Price/Cash Flow N/A
Price/Book 79.53
Book Value/Share 0.34
Interest Coverage 0.00
60-Month Beta -0.12
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.